2021 CEHC实践指南：血小板生成素受体激动剂在接受侵入性治疗的慢性肝病患者中的应用

2021-11-19 中欧肝病合作组织 Journal of Clinical Medicine

2021年11月，中欧肝病合作组织(CEHC)发布了血小板生成素受体激动剂在接受侵入性治疗的慢性肝病患者中的应用指南。

中文标题：

英文标题：

Practice Guidelines of the Central European Hepatologic Collaboration (CEHC) on the Use of Thrombopoietin Receptor Agonists in Patients with Chronic Liver Disease Undergoing Invasive Procedures

发布机构：

中欧肝病合作组织

发布日期：

2021-11-19

简要介绍：

2021年11月，中欧肝病合作组织(CEHC)发布了血小板生成素受体激动剂在接受侵入性治疗的慢性肝病患者中的应用指南。第二代血小板生成素受体激动剂（TPO-RAs）正在成为整理慢性肝病患者血小板减少症（TCP）的新标准治疗。本文主要针对TPO-RAs在接受侵入性治疗的慢性肝病患者中的应用提供指导建议。

相关资料下载：

GetToolGuiderByIdResponse(projectId=1, id=77e7d1c0022ea410, title=2021 CEHC实践指南：血小板生成素受体激动剂在接受侵入性治疗的慢性肝病患者中的应用, enTitle=Practice Guidelines of the Central European Hepatologic Collaboration (CEHC) on the Use of Thrombopoietin Receptor Agonists in Patients with Chronic Liver Disease Undergoing Invasive Procedures, guiderFrom=Journal of Clinical Medicine, authorId=0, author=, summary=2021年11月，中欧肝病合作组织(CEHC)发布了血小板生成素受体激动剂在接受侵入性治疗的慢性肝病患者中的应用指南。, cover=https://img.medsci.cn/20211129/1638152343793_1608702.png, journalId=0, articlesId=null, associationId=2154, associationName=中欧肝病合作组织, associationIntro=中欧肝病合作组织(CEHC,Central European Hepatologic Collaboration), copyright=0, guiderPublishedTime=Fri Nov 19 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">2021年11月，中欧肝病合作组织(CEHC)发布了血小板生成素受体激动剂在接受侵入性治疗的慢性肝病患者中的应用指南。第二代血小板生成素受体激动剂（TPO-RAs）正在成为整理慢性肝病患者血小板减少症（TCP）的新标准治疗。本文主要针对TPO-RAs在接受侵入性治疗的慢性肝病患者中的应用提供指导建议。</span></p>, tagList=[TagDto(tagId=8375, tagName=慢性肝病)], categoryList=[CategoryDto(categoryId=4, categoryName=消化, tenant=100), CategoryDto(categoryId=22, categoryName=肝病, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=91, categoryName=肝胆胰外, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=8375, guiderKeyword=慢性肝病, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=2, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=2358, appHits=44, showAppHits=0, pcHits=277, showPcHits=2314, likes=0, shares=4, comments=3, approvalStatus=1, publishedTime=Mon Nov 29 11:03:02 CST 2021, publishedTimeString=2021-11-19, pcVisible=1, appVisible=1, editorId=1608702, editor=dajiong, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=4, createdBy=null, createdName=dajiong, createdTime=Mon Nov 29 10:18:06 CST 2021, updatedBy=6415643, updatedName=凯晨, updatedTime=Sat Jan 06 07:13:14 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 CEHC实践指南：血小板生成素受体激动剂在接受侵入性治疗的慢性肝病患者中的应用.pdf)])

2021 CEHC实践指南：血小板生成素受体激动剂在接受侵入性治疗的慢性肝病患者中的应用.pdf

下载请点击：

评论区 (3)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1084057, encodeId=9cb6108405e17, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210302/d7aef29f1c284560b978861e2a96fbb2/c495254e3ce54350a8a4f1eb91e884c8.jpg, createdBy=15e55464744, createdName=坚定的心, createdTime=Fri Dec 24 21:49:04 CST 2021, time=2021-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082354, encodeId=e5b91082354f1, content=学习好资料！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Tue Dec 21 08:40:11 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075304, encodeId=fd1a10e53042e, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Tue Nov 30 07:04:22 CST 2021, time=2021-11-30, status=1, ipAttribution=)]
2021-12-24 坚定的心

学习了

48 0
[GetPortalCommentsPageByObjectIdResponse(id=1084057, encodeId=9cb6108405e17, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210302/d7aef29f1c284560b978861e2a96fbb2/c495254e3ce54350a8a4f1eb91e884c8.jpg, createdBy=15e55464744, createdName=坚定的心, createdTime=Fri Dec 24 21:49:04 CST 2021, time=2021-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082354, encodeId=e5b91082354f1, content=学习好资料！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Tue Dec 21 08:40:11 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075304, encodeId=fd1a10e53042e, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Tue Nov 30 07:04:22 CST 2021, time=2021-11-30, status=1, ipAttribution=)]
2021-12-21 龙珠

学习好资料！

45 0
[GetPortalCommentsPageByObjectIdResponse(id=1084057, encodeId=9cb6108405e17, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210302/d7aef29f1c284560b978861e2a96fbb2/c495254e3ce54350a8a4f1eb91e884c8.jpg, createdBy=15e55464744, createdName=坚定的心, createdTime=Fri Dec 24 21:49:04 CST 2021, time=2021-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082354, encodeId=e5b91082354f1, content=学习好资料！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Tue Dec 21 08:40:11 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075304, encodeId=fd1a10e53042e, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Tue Nov 30 07:04:22 CST 2021, time=2021-11-30, status=1, ipAttribution=)]
2021-11-30 微探

学习学习

48 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

消化指南

2021 CEHC实践指南：血小板生成素受体激动剂在接受侵入性治疗的慢性肝病患者中的应用

相关指南

拓展阅读

科室

工具

服务